|
Name |
Asperentin
|
| Molecular Formula | C16H20O5 | |
| IUPAC Name* |
6,8-dihydroxy-3-[[(2R,6S)-6-methyloxan-2-yl]methyl]-3,4-dihydroisochromen-1-one
|
|
| SMILES |
C[C@H]1CCC[C@@H](O1)CC2CC3=C(C(=CC(=C3)O)O)C(=O)O2
|
|
| InChI |
InChI=1S/C16H20O5/c1-9-3-2-4-12(20-9)8-13-6-10-5-11(17)7-14(18)15(10)16(19)21-13/h5,7,9,12-13,17-18H,2-4,6,8H2,1H3/t9-,12+,13?/m0/s1
|
|
| InChIKey |
WOMKDMUZNBFXKG-XAWKZAOJSA-N
|
|
| Synonyms |
Asperentin; CHEMBL3911068; CHEBI:68792; Q27137182; 3,4-dihydro-6,8-dihydroxy-3-(tetrahydro-6-methyl-H-pyran-2-yl)methylisocoumarin; 6,8-dihydroxy-3-{[(2R,6S)-6-methyltetrahydro-2H-pyran-2-yl]methyl}-3,4-dihydro-1H-isochromen-1-one
|
|
| CAS | NA | |
| PubChem CID | 71728346 | |
| ChEMBL ID | CHEMBL3911068 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 292.33 | ALogp: | 3.3 |
| HBD: | 2 | HBA: | 5 |
| Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 76.0 | Aromatic Rings: | 3 |
| Heavy Atoms: | 21 | QED Weighted: | 0.818 |
| Caco-2 Permeability: | -4.804 | MDCK Permeability: | 0.00003890 |
| Pgp-inhibitor: | 0.003 | Pgp-substrate: | 0.003 |
| Human Intestinal Absorption (HIA): | 0.009 | 20% Bioavailability (F20%): | 0.016 |
| 30% Bioavailability (F30%): | 0.429 |
| Blood-Brain-Barrier Penetration (BBB): | 0.314 | Plasma Protein Binding (PPB): | 86.68% |
| Volume Distribution (VD): | 1.03 | Fu: | 8.31% |
| CYP1A2-inhibitor: | 0.498 | CYP1A2-substrate: | 0.222 |
| CYP2C19-inhibitor: | 0.14 | CYP2C19-substrate: | 0.186 |
| CYP2C9-inhibitor: | 0.092 | CYP2C9-substrate: | 0.922 |
| CYP2D6-inhibitor: | 0.526 | CYP2D6-substrate: | 0.418 |
| CYP3A4-inhibitor: | 0.502 | CYP3A4-substrate: | 0.174 |
| Clearance (CL): | 14.238 | Half-life (T1/2): | 0.722 |
| hERG Blockers: | 0.021 | Human Hepatotoxicity (H-HT): | 0.583 |
| Drug-inuced Liver Injury (DILI): | 0.718 | AMES Toxicity: | 0.367 |
| Rat Oral Acute Toxicity: | 0.032 | Maximum Recommended Daily Dose: | 0.979 |
| Skin Sensitization: | 0.91 | Carcinogencity: | 0.91 |
| Eye Corrosion: | 0.024 | Eye Irritation: | 0.708 |
| Respiratory Toxicity: | 0.685 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003280 | ![]() |
1.000 | D07MGA | ![]() |
0.290 | ||
| ENC003043 | ![]() |
0.739 | D03YVO | ![]() |
0.267 | ||
| ENC003297 | ![]() |
0.714 | D04JHN | ![]() |
0.266 | ||
| ENC005249 | ![]() |
0.565 | D0PG8O | ![]() |
0.262 | ||
| ENC003870 | ![]() |
0.560 | D00ZFP | ![]() |
0.261 | ||
| ENC003117 | ![]() |
0.538 | D02NSF | ![]() |
0.247 | ||
| ENC003158 | ![]() |
0.519 | D01KQA | ![]() |
0.243 | ||
| ENC005003 | ![]() |
0.513 | D05VIL | ![]() |
0.238 | ||
| ENC005644 | ![]() |
0.506 | D08QMX | ![]() |
0.234 | ||
| ENC003872 | ![]() |
0.500 | D0X3FX | ![]() |
0.233 | ||